Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Autolus Therapeutics Plc ADR
(NQ:
AUTL
)
4.670
+0.110 (+2.41%)
Streaming Delayed Price
Updated: 10:32 AM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
186,259
Open
4.580
Bid (Size)
4.670 (2)
Ask (Size)
4.680 (9)
Prev. Close
4.560
Today's Range
4.560 - 4.710
52wk Range
1.610 - 7.450
Shares Outstanding
52,346,231
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
Today 7:00 EDT
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
April 11, 2024
Via
Benzinga
Performance
YTD
-31.73%
-31.73%
1 Month
-26.22%
-26.22%
3 Month
-18.78%
-18.78%
6 Month
+84.58%
+84.58%
1 Year
+162.36%
+162.36%
More News
Read More
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
April 02, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
March 18, 2024
Via
Benzinga
Autolus Therapeutics's Earnings Outlook
March 13, 2024
Via
Benzinga
Analyst Expectations for Autolus Therapeutics's Future
December 13, 2023
Via
Benzinga
Autolus Therapeutics Announces Changes to its Board of Directors
April 01, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 20, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
March 15, 2024
Via
Benzinga
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
March 14, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Earnings Scheduled For March 14, 2024
March 14, 2024
Via
Benzinga
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
March 12, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Blood Cancer Journal
March 11, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
February 29, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in Nature Communications
February 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Announces Pricing of Underwritten Offering
February 08, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces publication in ACS Chemical Biology
January 23, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
January 22, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
January 12, 2024
Via
Talk Markets
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
January 10, 2024
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 27, 2023
Via
Benzinga
Autolus Therapeutics Announces Changes to its Board of Directors
December 22, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
December 09, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
November 28, 2023
Via
Benzinga
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
November 27, 2023
From
Autolus Therapeutics plc
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.